You are here

With More Biosimilars Approved, FDA Urged to Track Adverse Events

Noting the complexities of biological products and the potential differences in products created from different living cells, Dr Miletich emphasised that biotechnology is an evolving field. "While much more is known today than 30 years ago, FDA's guidance documents should candidly acknowledge that there are some things we still do not scientifically know today," he told the hearing.

As the FDA finalises its guidances for the development of biosimilars, it must adopt policies to facilitate attribution of adverse events and foster manufacturer accountability, he added. The arrival of biosimilars in the US marketplace will significantly increase the challenge and importance of accurate tracking and tracing, and the use of distinguishable established names will facilitate prompt identification and resolution of product problems, he suggested.

Read the entire article here.

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
Synergistic Effects Seen When Combined With Cisplatin in Mice